CSIR-IICT, Lee Pharma sign agreement to produce 2-D

Lee Pharma informed that they would file the application for getting approval from the drug regulator.

50
Deal
Picture: Pixabay

Lee Pharma has entered into a non-exclusive licensing agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-Deoxy-D-Glucose (2-DG) recently developed by DRDO and Dr Reddy’s Laboratories to treat C-19 patients, informed a statement.

The drug has received approval for use in C-19 patients. It has been found to help speed up recovery and reduce oxygen dependence, and Dr Reddy’s Laboratories has launched the drug in the form of sachets.

Lee Pharma informed that they would file the application for getting approval from the drug regulator.

Medicine Factory
Picture: Pixabay

Lee Pharma will manufacture and commercialise the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam, Andhra Pradesh, which has accreditation by global regulatory agencies, the Council for Scientific and Industrial Research (CSIR) said in a statement.

Srivari Chandrashekar, Director CSIR-IICT said, “There is role of CSIR in development of 2-DG, as CSIR-CCMB tested the drug on SARS-CoV-2 viral cultures”.

“The CSIR has been engaged in the development of drugs for the treatment of C-19 and has undertaken many clinical trials for repurposed drugs. Additionally, this agreement with Lee Pharma is towards increasing affordable therapeutic options for treatment of C-19,” he said.

Black fungus: SP Accure Labs launches Amphotericin B emulsion

Status of Industrial pollution by Pharma companies: CPCB

These top 5 sectors most affected by counterfeiting: Report

Hospital in controversy to be sealed, patients being shifted

Lupin launches Digital Asthma Educator platform for patients

OxygenForIndia ensures no one dies due to lack of oxygen

Subscribe for daily free updates on Telegram

Follow us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Enter your email address:

Delivered by FeedBurner